ATE533500T1 - Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür - Google Patents

Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür

Info

Publication number
ATE533500T1
ATE533500T1 AT04711176T AT04711176T ATE533500T1 AT E533500 T1 ATE533500 T1 AT E533500T1 AT 04711176 T AT04711176 T AT 04711176T AT 04711176 T AT04711176 T AT 04711176T AT E533500 T1 ATE533500 T1 AT E533500T1
Authority
AT
Austria
Prior art keywords
methods
inhibitors
molecules
mhc class
antigen presentation
Prior art date
Application number
AT04711176T
Other languages
English (en)
Inventor
Gary Olson
Charles Cook
Christopher Self
Original Assignee
Provid Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provid Pharmaceuticals Inc filed Critical Provid Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE533500T1 publication Critical patent/ATE533500T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT04711176T 2003-02-14 2004-02-13 Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür ATE533500T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44794903P 2003-02-14 2003-02-14
PCT/US2004/004389 WO2004073625A2 (en) 2003-02-14 2004-02-13 Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE533500T1 true ATE533500T1 (de) 2011-12-15

Family

ID=32908515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04711176T ATE533500T1 (de) 2003-02-14 2004-02-13 Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür

Country Status (11)

Country Link
US (3) US7439231B2 (de)
EP (1) EP1605963B1 (de)
AT (1) ATE533500T1 (de)
AU (1) AU2004212954B2 (de)
CA (1) CA2516080C (de)
DK (1) DK1605963T3 (de)
NO (1) NO20054238L (de)
NZ (1) NZ542256A (de)
PL (1) PL211458B1 (de)
RU (1) RU2333219C2 (de)
WO (1) WO2004073625A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211458B1 (pl) * 2003-02-14 2012-05-31 Provid Pharmaceuticals Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków
US20100183658A1 (en) * 2007-03-30 2010-07-22 The Brigham And Women's Hospital, Inc. Novel Compounds for Enhancing MHC Class II Therapies
EP2229399A1 (de) * 2007-12-03 2010-09-22 Provid Pharmaceuticals, Inc. Inhibitoren der antigenpräsentation durch mhc-klasse-ii-moleküle und verfahren zu deren anwendung
EP2655395B1 (de) 2010-12-23 2018-03-07 Universiteit Gent Verfahren zur vernetzung von peptiden
CN114615976A (zh) 2019-08-07 2022-06-10 人福医药美国公司 κ阿片受体肽酰胺激动剂
US12616732B2 (en) 2020-06-25 2026-05-05 Yichang Humanwell Pharmaceuticals Co., Ltd. Peptides for treatment of medical disorders
WO2021262173A1 (en) 2020-06-25 2021-12-30 Humanwell Pharmaceutical US Peptides for treatment of medical disorders
WO2022197499A1 (en) * 2021-03-19 2022-09-22 Provid Pharmaceuticals Inc. Inhibitors of antigen presentation by mhc class ii hla-drb1*15:01 molecules with enhanced metabolic stability
US12545716B2 (en) 2021-07-19 2026-02-10 Immunome, Inc. Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4839344A (en) * 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US6077509A (en) 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JP3908271B2 (ja) * 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
DE4340111A1 (de) * 1993-11-22 1995-05-24 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
DE4342846A1 (de) * 1993-12-10 1995-06-14 Schering Ag Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
US5585980A (en) * 1994-06-09 1996-12-17 International Business Machines Corporation Low friction device for an actuator arm of a disk drive
US5559114A (en) * 1994-12-16 1996-09-24 Exley; Ray W. Treatment of autoimmune disease using 2-amino purine derivatives
US5874531A (en) 1995-03-07 1999-02-23 President And Fellows Of Harvard College Identification of self and non-self antigens implicated autoimmune disease
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
JPH11510792A (ja) * 1995-06-29 1999-09-21 トーマス ジェファーソン ユニバーシティー 免疫応答を阻害するｃｄ４−誘導ペプチド
US5859980A (en) * 1996-02-08 1999-01-12 Advanced Micro Devices, Inc. Network interface having adaptive transmit start point for each packet to avoid transmit underflow
GB9620819D0 (en) * 1996-10-05 1996-11-20 Zeneca Ltd Chemical compounds
FR2753707B1 (fr) * 1996-09-23 1998-12-11 Complexes nucleopeptidiques, compositions cosmetologiques et pharmaceutiques les contenant et utilisations
GB9621836D0 (en) * 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) * 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
US6891046B2 (en) 2000-04-26 2005-05-10 Smith, Iii Amos B. Solution and solid phase synthesis of pyrrolinones and polypyrrolinones
MXPA04009228A (es) 2002-03-22 2005-08-16 Gpc Biotech Ag Compuestos inmunosupresores, metodos y usos relacionados con los mismos.
PL211458B1 (pl) * 2003-02-14 2012-05-31 Provid Pharmaceuticals Związki, kompozycja farmaceutyczna zawierająca je oraz zastosowanie związków

Also Published As

Publication number Publication date
AU2004212954A1 (en) 2004-09-02
WO2004073625A2 (en) 2004-09-02
EP1605963A4 (de) 2007-02-14
AU2004212954B2 (en) 2008-07-17
EP1605963B1 (de) 2011-11-16
PL378195A1 (pl) 2006-03-06
NO20054238D0 (no) 2005-09-13
PL211458B1 (pl) 2012-05-31
US20120252734A1 (en) 2012-10-04
RU2333219C2 (ru) 2008-09-10
WO2004073625A3 (en) 2005-01-20
US8598312B2 (en) 2013-12-03
NO20054238L (no) 2005-11-11
RU2005128549A (ru) 2006-02-10
CA2516080A1 (en) 2004-09-02
NZ542256A (en) 2009-05-31
DK1605963T3 (da) 2012-02-06
US8222215B2 (en) 2012-07-17
US20040162242A1 (en) 2004-08-19
CA2516080C (en) 2021-11-02
US7439231B2 (en) 2008-10-21
EP1605963A2 (de) 2005-12-21
US20090111755A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
PH12014500053A1 (en) Proteasome inhibitors
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
IS3013B (is) Meltikornatálmar og aðferðir til að nota þá
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
MY149957A (en) Heterocyclic inhibitors of mek and methods of use thereof
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
SE0301700D0 (sv) Novel compounds
ATE504565T1 (de) Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
ATE387435T1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE335748T1 (de) Thienopyrimidindione und deren verwendung bei der modulierung von autoimmunerkrankungen
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
BRPI0410905A (pt) inibidores de p-38
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
EP1605963A4 (de) Hemmer der antigenpräsentation über mhc-klasse-ii-moleküle und verwendungsverfahren dafür
DE60135158D1 (de) Antagonisten des ige-rezeptors